Singular Research reissued their buy rating on shares of Amyris Inc. (NASDAQ:AMRS) in a research note released on Wednesday. Singular Research currently has a $2.80 price target on the stock.

Separately, Zacks Investment Research raised Amyris from a hold rating to a buy rating and set a $0.50 price target for the company in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $2.66.

Shares of Amyris (NASDAQ:AMRS) opened at 0.60 on Wednesday. The firm has a 50-day moving average price of $0.46 and a 200-day moving average price of $0.62. The firm’s market cap is $141.01 million. Amyris has a 52-week low of $0.31 and a 52-week high of $2.57.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.06. The company had revenue of $9.60 million for the quarter, compared to analysts’ expectations of $15.23 million. The business’s quarterly revenue was up 23.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.47) EPS. Analysts predict that Amyris will post ($0.20) EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in AMRS. Jacobs Levy Equity Management Inc. bought a new position in Amyris during the first quarter valued at $269,000. Geode Capital Management LLC increased its stake in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock worth $331,000 after buying an additional 30,958 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares in the last quarter. 35.68% of the stock is owned by institutional investors.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.